 |
85 Diseases |  |
26 Trials |
|
26 Trials |  |
4615 News |  |
| «12...3839404142434445464748...5758» |
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4866;
Based on these results and considering the published data (Jodele S. et al., 2016, 2018) - the risk and response-based dose-intensity adjustment of Eculizumab and improving the chance to identify the proposed high-risk TA-TMA with detailed complement monitoring (CH50, sC5b-9, eculizumab drug level monitoring) deserve attention in future prospective trials. Focus on better understanding the interplay between acute GvHD and TA-TMA should be part of the trial designs.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4865;
Based on these results and considering the published data (Jodele S. et al., 2016, 2018) - the risk and response-based dose-intensity adjustment of Eculizumab and improving the chance to identify the proposed high-risk TA-TMA with detailed complement monitoring (CH50, sC5b-9, eculizumab drug level monitoring) deserve attention in future prospective trials. Focus on better understanding the interplay between acute GvHD and TA-TMA should be part of the trial designs.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4864;
Based on these results and considering the published data (Jodele S. et al., 2016, 2018) - the risk and response-based dose-intensity adjustment of Eculizumab and improving the chance to identify the proposed high-risk TA-TMA with detailed complement monitoring (CH50, sC5b-9, eculizumab drug level monitoring) deserve attention in future prospective trials. Focus on better understanding the interplay between acute GvHD and TA-TMA should be part of the trial designs.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4863;
Patients with TA-TMA have higher morbidity and mortality when compared to patients without TA-TMA. Clinical Trial Registry: n/a
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4862;
Patients with TA-TMA have higher morbidity and mortality when compared to patients without TA-TMA. Clinical Trial Registry: n/a
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4861;
Patients with TA-TMA have higher morbidity and mortality when compared to patients without TA-TMA. Clinical Trial Registry: n/a
- tacrolimus / Generic mfg., Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4615;
Therefore, TPE in combination with t-PA/UK might be considered substitution therapy for TA-TMA patients who do not have access to defibrotide, eculizumab or other recommended medication. More efforts should be made to prevent TA-TMA relapse and decrease major bleeding.
- tacrolimus / Generic mfg., Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4614;
Therefore, TPE in combination with t-PA/UK might be considered substitution therapy for TA-TMA patients who do not have access to defibrotide, eculizumab or other recommended medication. More efforts should be made to prevent TA-TMA relapse and decrease major bleeding.
- tacrolimus / Generic mfg., Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4613;
Therefore, TPE in combination with t-PA/UK might be considered substitution therapy for TA-TMA patients who do not have access to defibrotide, eculizumab or other recommended medication. More efforts should be made to prevent TA-TMA relapse and decrease major bleeding.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4588;
Moreover, the availability of complement analysis is limited, further delaying targeted therapy. A high index of suspicion is warranted to facilitate early administration of eculizumab.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4587;
Moreover, the availability of complement analysis is limited, further delaying targeted therapy. A high index of suspicion is warranted to facilitate early administration of eculizumab.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4586;
Moreover, the availability of complement analysis is limited, further delaying targeted therapy. A high index of suspicion is warranted to facilitate early administration of eculizumab.
- [VIRTUAL] HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4564;
Severe hemolysis and low reticulocyte counts after stable erythroid engraftment should raise a suspicion of life-threatening HHS and differentiate it from other recognized entities such as autoimmune hemolytic anemia or AB0 incompatibility, where hemolytic episodes are usually milder and associate with increased reticulocytes. Although the mechanism will require further elucidation, these cases showed an association of HHS with the generation of anti-E auto(allo)-antibodies.
- [VIRTUAL] HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4563;
Severe hemolysis and low reticulocyte counts after stable erythroid engraftment should raise a suspicion of life-threatening HHS and differentiate it from other recognized entities such as autoimmune hemolytic anemia or AB0 incompatibility, where hemolytic episodes are usually milder and associate with increased reticulocytes. Although the mechanism will require further elucidation, these cases showed an association of HHS with the generation of anti-E auto(allo)-antibodies.
- [VIRTUAL] HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4562;
Severe hemolysis and low reticulocyte counts after stable erythroid engraftment should raise a suspicion of life-threatening HHS and differentiate it from other recognized entities such as autoimmune hemolytic anemia or AB0 incompatibility, where hemolytic episodes are usually milder and associate with increased reticulocytes. Although the mechanism will require further elucidation, these cases showed an association of HHS with the generation of anti-E auto(allo)-antibodies.
- narsoplimab (OMS721) / Omeros, Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721) (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4450;
Narsoplimab is a novel selective inhibitor of the complement lectin pathway with FDA breakthrough therapy designation for HCT-TMA. In patients with severe HCT-TMA that do not respond to conventional measures, our experience is very encouraging, both in terms of safety and efficacy on laboratory and clinical parameters, including full and sustained resolution with prolonged survival in cases that otherwise have a dismal prognosis of survival of only a few weeks.
- narsoplimab (OMS721) / Omeros, Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721) (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4449;
Narsoplimab is a novel selective inhibitor of the complement lectin pathway with FDA breakthrough therapy designation for HCT-TMA. In patients with severe HCT-TMA that do not respond to conventional measures, our experience is very encouraging, both in terms of safety and efficacy on laboratory and clinical parameters, including full and sustained resolution with prolonged survival in cases that otherwise have a dismal prognosis of survival of only a few weeks.
- narsoplimab (OMS721) / Omeros, Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721) (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4448;
Narsoplimab is a novel selective inhibitor of the complement lectin pathway with FDA breakthrough therapy designation for HCT-TMA. In patients with severe HCT-TMA that do not respond to conventional measures, our experience is very encouraging, both in terms of safety and efficacy on laboratory and clinical parameters, including full and sustained resolution with prolonged survival in cases that otherwise have a dismal prognosis of survival of only a few weeks.
- Jakafi oral (ruxolitinib) / Novartis, Incyte, Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3205;
Given the confounding comorbidities in these patients, increased awareness is needed by treating physicians to identify TA-TMA. Further studies are warranted to confirm these findings and unravel possible pathogenetic mechanisms.
- Jakafi oral (ruxolitinib) / Novartis, Incyte, Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3204;
Given the confounding comorbidities in these patients, increased awareness is needed by treating physicians to identify TA-TMA. Further studies are warranted to confirm these findings and unravel possible pathogenetic mechanisms.
- Jakafi oral (ruxolitinib) / Novartis, Incyte, Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3203;
Given the confounding comorbidities in these patients, increased awareness is needed by treating physicians to identify TA-TMA. Further studies are warranted to confirm these findings and unravel possible pathogenetic mechanisms.
- ||||| Soliris (eculizumab) / Alexion Pharma
WATCH: @sgiraltbmtdoc, of @sloan_kettering, explains remaining challenges with eculizumab in hematologic malignancies. @TCTConference #TCTM20 https://t.co/xgdFdUIghp (Twitter) - Jun 30, 2020
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting. (Pubmed Central) - Jun 29, 2020
Two underwent allogenic stem cell transplantation. In the PNH/AA group, 16 (50%) were in CR and seven (21%) were in PR with anti-thymocyte globulin ± cyclosporine.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. (Pubmed Central) - Jun 28, 2020
Emerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.
- | Jakafi oral (ruxolitinib) / Novartis, Incyte, Soliris (eculizumab) / Alexion Pharma
Journal: Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. (Pubmed Central) - Jun 27, 2020
Patients treated with the combination showed significant improvements in respiratory symptoms and radiographic pulmonary lesions and decrease in circulating D-dimer levels compared to the best available therapy group. Our results support the use of combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related ARDS by simultaneously turning off abnormal innate and adaptive immune responses.
- Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] The Relative Impact of Treatment Approaches on the Outcome of Catastrophic Antiphospholipid Syndrome (CAPS): Analysis of an Updated Database (Virtual Meeting Room 3) - Jun 27, 2020 - Abstract #ISTH2020ISTH_3158;
We recommend a paradigm shift in CAPS frontline treatment which should consist of AC+GC+ECL+RTX+ therapies targeting the underlying medical condition. Time is of the essence, and highly active agents should be used upfront in CAPS to significantly lower mortality and morbidity.
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Use of Eculizumab for Active Antibody-Mediated Rejection that Occurs Early Post-Kidney Transplantation: A Consecutive Series of 15 Cases. (Pubmed Central) - Jun 26, 2020
Time is of the essence, and highly active agents should be used upfront in CAPS to significantly lower mortality and morbidity. Prompt eculizumab treatment as primary therapy is safe and effective for early active AMR after kidney transplant or abrupt increases in donor-specific antibodies when biopsy cannot be performed for diagnosis confirmation.
- | Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio
Journal: Diagnosis and treatment of myasthenia gravis. (Pubmed Central) - Jun 26, 2020
CBAs can lead to a significant reduction of seronegative patients, improving myasthenia gravis diagnostic process. New biological drugs offer innovative approaches to treat myasthenic patients with generalized disease, promising to change the paradigm of treatment and to significantly enhance therapeutic success within a precision medicine framework.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. (Pubmed Central) - Jun 26, 2020
Eculizumab treatment abrogates not only intravascular hemolysis, but also auto-inflammation. Thus, PIGT-PNH differs from PIGA-PNH both in the mechanism of clonal expansion and in clinical manifestations.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Monoclonal antibodies for monogenic diseases: a 2019 update (Pubmed Central) - Jun 25, 2020
More recently, lanadelumab, an anti-plasma kallikrein antibody, has reinforced the therapeutic arsenal in hereditary angioedema and burosumab, anti-FGF23, that of X-linked hypophosphatemia. Such examples reflect the importance of monoclonal antibody therapy of monogenic diseases, the interest of considering such an option as well as the need for future researches.
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: A case report of recurrent acute pancreatitis associated with life threatening atypical hemolytic uremic syndrome. (Pubmed Central) - Jun 25, 2020
Such examples reflect the importance of monoclonal antibody therapy of monogenic diseases, the interest of considering such an option as well as the need for future researches. Recurrent pancreatitis is suggested as the etiology of atypical HUS in this patient and this condition should be recognized and treated in a timely manner for optimal clinical outcomes.
- | Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Review, Journal: Myasthenia gravis: State of the art and new therapeutic strategies. (Pubmed Central) - Jun 19, 2020
Many breakthroughs in the discovery of new therapeutic targets have been reported, but MG remains to be a chronic disease where the symptoms are kept in the majority of patients. In this review, we discuss the different therapeutic strategies that have been used over the years to alleviate MG symptoms, as well as innovative therapeutic approaches currently under study.
- Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
Trial initiation date: Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab (clinicaltrials.gov) - Jun 18, 2020
P4, N=20, Not yet recruiting, Sponsor: Alexion Pharmaceuticals
In this review, we discuss the different therapeutic strategies that have been used over the years to alleviate MG symptoms, as well as innovative therapeutic approaches currently under study. Initiation date: May 2020 --> Jan 2021
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Disseminated gonococcal infections in patients receiving eculizumab: a case series. (Pubmed Central) - Jun 18, 2020
Prescribers are encouraged to educate patients receiving eculizumab on their risk for serious gonococcal infections and perform screening for sexually transmitted diseases (STDs) per Centers for Disease Control and Prevention STD treatment guidelines or in suspect cases. If antimicrobial prophylaxis is used during eculizumab therapy, prescribers should consider trends in gonococcal antimicrobial susceptibility due to emerging resistance concerns.
- | Soliris (eculizumab) / Alexion Pharma
Journal: No good deed goes unpunished: eculizumab and invasive neisserial infections. (Pubmed Central) - Jun 18, 2020
If antimicrobial prophylaxis is used during eculizumab therapy, prescribers should consider trends in gonococcal antimicrobial susceptibility due to emerging resistance concerns. No abstract available
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Differential effects of therapeutic complement Inhibitors on serum bactericidal activity against nongroupable meningococcal isolates recovered from patients treated with eculizumab. (Pubmed Central) - Jun 18, 2020
No abstract available No abstract available
- | Soliris (eculizumab) / Alexion Pharma
Journal: Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy. (Pubmed Central) - Jun 18, 2020
There was a significant association between higher presenting creatinine and poorer renal outcomes. A strategy of eculizumab withdrawal in selected cases is both safe and cost effective.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Thrombotic microangiopathy and pregnancy. (Pubmed Central) - Jun 18, 2020
The authors present a basic overview of the issue of TMA, which requires interdisciplinary cooperation of obstetricians, anesthesiologists, nephrologists and hematologists. In the second part of the article, we present two TMA case reports and finally show the differential diagnostic and therapeutic scheme as agreed by the authorities in the field.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Severe thrombotic microangiopathy accompanied by liver rupture and multiorgan failure at week 26 of pregnancy. (Pubmed Central) - Jun 18, 2020
Other research suggests patients may also require a terminal complement blockade with the anti-C5 monoclonal antibody (eculizumab). Further research could focus on diagnostic tests to distinguish PTMS from HELLP to identify which patients would most benefit from these treatments.
- |||||||||| crovalimab (RG6107) / Roche
New P3 trial: COMMODORE 1: A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (clinicaltrials.gov) - Jun 15, 2020
P3, N=250, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||||||| crovalimab (RG6107) / Roche
New P3 trial: COMMODORE 2: A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (clinicaltrials.gov) - Jun 15, 2020
P3, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||| Uplizna (inebilizumab) / Viela Bio, Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Clinical, FDA event: #Uplizna & rituximab both deplete B cells, but only Uplinza was studied in a placebo-controlled formal trial in #NMO. #Soliris which affects complement is the other FDA-approved treatment for #NMOSD. Great to have highly effective options for a potentially devastating disease 👍 (Twitter) - Jun 15, 2020
- Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] THROMBOTIC MICROANGIOPATHY IN A PATIENT WITH PERSISTENT CRYOGLOBULINEMIA AFTER HCV ERADICATION AND HETEROZYGOUS DELETION OF CFHR3-CFHR1 REGION: SHOULD WE TREAT WITH RITUXIMAB, ECULIZUMAB OR PLASMAPHERESIS? () - Jun 13, 2020 - Abstract #ERAEDTA2020ERA-EDTA_907;
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] FIRST RUSSIAN BOSIMILAR OF ECULIZUMAB IN THE TREATMENT OF AN ADULT PATIENT WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME () - Jun 13, 2020 - Abstract #ERAEDTA2020ERA-EDTA_674;
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] ECULIZUMAB USE IN A TERTIARY CARE NEPHROLOGY CENTER (Poster 4) - Jun 13, 2020 - Abstract #ERAEDTA2020ERA-EDTA_549;
- | Soliris (eculizumab) / Alexion Pharma
Journal: Update on C1 Esterase Inhibitor (C1-INH) in Human Solid Organ Transplantation. (Pubmed Central) - Jun 10, 2020
C1-INH contrasts with eculizumab and other distal inhibitors, which do not affect C4b or C3b deposition or noncomplement pathways...This article reviews clinical data and ongoing trials with C1-INH in transplant recipients, compares the results with those of other complement inhibitors, and summarizes potentially productive directions for future research.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Clinical data, Journal: Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. (Pubmed Central) - Jun 10, 2020
The work cannot be changed in any way or used commercially without permission from the journal. Results from this observational study are consistent with benefit from eculizumab prophylaxis based on pretransplant risk stratification and support the need for a rigorous randomized trial.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Hemolytic uremic syndrome in a developing country: Consensus guidelines. (Pubmed Central) - Jun 8, 2020
Limited diagnostic capabilities and lack of access to eculizumab prevent the implementation of international guidelines for HUS in most developing countries. We propose practice guidelines for India, which will perhaps be applicable to other developing countries.
- || Soliris (eculizumab) / Alexion Pharma
Review, Journal: Complement dysregulation in glomerulonephritis. (Pubmed Central) - Jun 8, 2020
Complement inhibition is an emerging treatment option. A thorough understanding of the basic disease mechanism and a careful follow-up are needed for optimal therapy.